Sylvestre Le Moulec

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier et al. · JAMA Oncology · 2018 · 738 citations · Full text

Medicine, Oncology, Pharmacology +14

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth et al. · JAMA Oncology · 2020 · 628 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan et al. · Nature Cancer · 2021 · 569 citations · Full text

Life Sciences, Immunology, Oncology +17

Blood diffusion and Th1-suppressive effects of galectin-9–containing exosomes released by Epstein-Barr virus–infected nasopharyngeal carcinoma cells

Jihène Klibi, Toshiro Niki, Alexander Riedel et al. · Blood · 2008 · 430 citations · Full text

Life Sciences, Immunology, Molecular Biology +15

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas

F Farace, Christophe Massard, Nadège Vimond et al. · British Journal of Cancer · 2011 · 399 citations · Full text

Medicine, Cell Biology, Oncology +15